IBTA e-News January 2018 released

[29 January 2018] The IBTA's monthly e-News has now been released and has been emailed to all subscribers. To sign up to receive your copy, click here.

You can read the IBTA e-News January 2018 edition in full online here.

Some of the highlights from this month's include:

A ‘survivorship care plan’ for adult neuro-oncology to assist patients transitioning from active treatment to the post-treatment phase of their cancer care has been published in Neuro-Oncology Practice.

The first high-energy proton beam therapy centre run by the UK National Health Service (NHS) is to open at the Christie Hospital in Manchester later this year.

Two studies have revealed the ‘body clock's’ role in brain tumour growth, potentially offering new targets for treatment and ways to optimise existing therapies.

A clinical trial of KB004 (Ifabotuzumab), an antibody that targets protein on cancer cells called EphA3, has enrolled its first patient at the Olivia Newton-John Cancer Research Institute (Austin Health) in Victoria, Australia, it has been announced.

It has been announced that a phase 3 clinical trial of the “first-in-class” chemotherapy agent VAL-083 has started recruiting patients. Open to recurrent glioblastoma patients who have failed standard temozolomide/radiation therapy and bevacizumab.

New research guidelines published in the journal The Lancet Oncology have made recommendations that more patients with brain metastases from solid tumours should be included in the clinical trials of systemic agents.

A retrospective analysis of the clinical outcomes of glioblastoma patients treated between April 2008 and March 2016, has concluded that bevacizumab (Avastin) should not be withheld from those with multiple (multifocal) glioblastoma tumours, where no reasonable therapy alternative exists.

UK politician Baroness Tessa Jowell has spoken publicly about her glioblastoma diagnosis and is calling for increased brain tumour research funding and easier access for brain tumour patients to new types of clinical trials, such as adaptive trials.

Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 7,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.